 Anticarcinogenic Agents
"Anticarcinogenic Agents" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Agents that reduce the frequency or rate of spontaneous or induced tumors independently of the mechanism involved.
| Descriptor ID |
D016588
|
| MeSH Number(s) |
D27.505.696.706.018 D27.505.954.248.125 D27.720.799.018
|
| Concept/Terms |
Anticarcinogenic Agents- Anticarcinogenic Agents
- Agents, Anticarcinogenic
- Anticarcinogens
- Anticarcinogenic Drugs
- Drugs, Anticarcinogenic
- Anti-Carcinogenic Agents
- Agents, Anti-Carcinogenic
- Anti Carcinogenic Agents
- Anti-Carcinogenic Drugs
- Anti Carcinogenic Drugs
- Drugs, Anti-Carcinogenic
Anticarcinogenic Effect- Anticarcinogenic Effect
- Effect, Anticarcinogenic
- Anti-Carcinogenic Effects
- Anti Carcinogenic Effects
- Effects, Anti-Carcinogenic
- Anticarcinogenic Effects
- Effects, Anticarcinogenic
- Anti-Carcinogenic Effect
- Anti Carcinogenic Effect
- Effect, Anti-Carcinogenic
|
Below are MeSH descriptors whose meaning is more general than "Anticarcinogenic Agents".
Below are MeSH descriptors whose meaning is more specific than "Anticarcinogenic Agents".
This graph shows the total number of publications written about "Anticarcinogenic Agents" by people in this website by year, and whether "Anticarcinogenic Agents" was a major or minor topic of these publications.
To see the data from this visualization as text, click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1994 | 1 | 0 | 1 | | 1995 | 4 | 0 | 4 | | 1996 | 1 | 0 | 1 | | 1999 | 1 | 0 | 1 | | 2000 | 3 | 2 | 5 | | 2001 | 3 | 0 | 3 | | 2002 | 1 | 1 | 2 | | 2003 | 1 | 1 | 2 | | 2006 | 1 | 1 | 2 | | 2007 | 1 | 0 | 1 | | 2009 | 2 | 0 | 2 | | 2011 | 2 | 0 | 2 | | 2012 | 2 | 0 | 2 | | 2013 | 5 | 0 | 5 | | 2016 | 1 | 0 | 1 | | 2017 | 1 | 0 | 1 | | 2018 | 1 | 0 | 1 | | 2019 | 1 | 0 | 1 |
To return to the timeline, click here.
Below are the most recent publications written about "Anticarcinogenic Agents" by people in Profiles.
-
Singhal SS, Horne D, Singhal J, Vonderfecht S, Salgia R, Awasthi S. Synergistic efficacy of RLIP inhibition and 2'-hydroxyflavanone against DMBA-induced mammary carcinogenesis in SENCAR mice. Mol Carcinog. 2019 08; 58(8):1438-1449.
-
Wali RK, Bianchi L, Kupfer S, De La Cruz M, Jovanovic B, Weber C, Goldberg MJ, Rodriguez LM, Bergan R, Rubin D, Tull MB, Richmond E, Parker B, Khan S, Roy HK. Prevention of colonic neoplasia with polyethylene glycol: A short term randomized placebo-controlled double-blinded trial. PLoS One. 2018; 13(4):e0193544.
-
Drew DA, Chin SM, Gilpin KK, Parziale M, Pond E, Schuck MM, Stewart K, Flagg M, Rawlings CA, Backman V, Carolan PJ, Chung DC, Colizzo FP, Freedman M, Gala M, Garber JJ, Huttenhower C, Kedrin D, Khalili H, Kwon DS, Markowitz SD, Milne GL, Nishioka NS, Richter JM, Roy HK, Staller K, Wang M, Chan AT. ASPirin Intervention for the REDuction of colorectal cancer risk (ASPIRED): a study protocol for a randomized controlled trial. Trials. 2017 02 01; 18(1):50.
-
William WN, Papadimitrakopoulou V, Lee JJ, Mao L, Cohen EE, Lin HY, Gillenwater AM, Martin JW, Lingen MW, Boyle JO, Shin DM, Vigneswaran N, Shinn N, Heymach JV, Wistuba II, Tang X, Kim ES, Saintigny P, Blair EA, Meiller T, Gutkind JS, Myers J, El-Naggar A, Lippman SM. Erlotinib and the Risk of Oral Cancer: The Erlotinib Prevention of Oral Cancer (EPOC) Randomized Clinical Trial. JAMA Oncol. 2016 Feb; 2(2):209-16.
-
Traka MH, Melchini A, Mithen RF. Sulforaphane and prostate cancer interception. Drug Discov Today. 2014 Sep; 19(9):1488-92.
-
Tung NH, Du GJ, Yuan CS, Shoyama Y, Wang CZ. Isolation and chemopreventive evaluation of novel naphthoquinone compounds from Alkanna tinctoria. Anticancer Drugs. 2013 Nov; 24(10):1058-68.
-
Wang J, Carvajal-Carmona LG, Chu JH, Zauber AG. Germline variants and advanced colorectal adenomas: adenoma prevention with celecoxib trial genome-wide association study. Clin Cancer Res. 2013 Dec 01; 19(23):6430-7.
-
Argos M, Rahman M, Parvez F, Dignam J, Islam T, Quasem I, K Hore S, T Haider A, Hossain Z, I Patwary T, Rakibuz-Zaman M, Sarwar G, La Porte P, Harjes J, Anton K, Kibriya MG, Jasmine F, Khan R, Kamal M, Shea CR, Yunus M, Baron JA, Ahsan H. Baseline comorbidities in a skin cancer prevention trial in Bangladesh. Eur J Clin Invest. 2013 Jun; 43(6):579-88.
-
Zhang Z, Wang CZ, Wen XD, Shoyama Y, Yuan CS. Role of saffron and its constituents on cancer chemoprevention. Pharm Biol. 2013 Jul; 51(7):920-4.
-
Wang CZ, Li B, Wen XD, Zhang Z, Yu C, Calway TD, He TC, Du W, Yuan CS. Paraptosis and NF-?B activation are associated with protopanaxadiol-induced cancer chemoprevention. BMC Complement Altern Med. 2013 Jan 03; 13:2.
|
People  People who have written about this concept. _
Similar Concepts
People who have written about this concept.
_
Top Journals
Top journals in which articles about this concept have been published.
|